Unique ID issued by UMIN | UMIN000008249 |
---|---|
Receipt number | R000009718 |
Scientific Title | The effect of Bepotastine besilate OD tablet for Japanese cedar pollinosis in an artificial exposure chamber(OHIO Chamber). |
Date of disclosure of the study information | 2012/06/26 |
Last modified on | 2013/01/16 14:40:02 |
The effect of Bepotastine besilate OD tablet for Japanese cedar pollinosis in an artificial exposure chamber(OHIO Chamber).
The effect of Bepotastine besilate OD tablet for Japanese cedar pollinosis in an artificial exposure chamber(OHIO Chamber).
The effect of Bepotastine besilate OD tablet for Japanese cedar pollinosis in an artificial exposure chamber(OHIO Chamber).
The effect of Bepotastine besilate OD tablet for Japanese cedar pollinosis in an artificial exposure chamber(OHIO Chamber).
Japan |
Japanese cedar Pollinosis
Oto-rhino-laryngology |
Others
NO
To clarify effect of Bepotastine besilate OD tablet on nasal symptoms of Japanese cedar pollen exposure in an artifical exposure chamber(OHIO Chamber).
Efficacy
Symptoms score (Nasal)
1)Nasal secretion volume
2)Number of sneezing
3)Occurrence time of first nasal symptom
4)Digit Cancellation test
Interventional
Parallel
Randomized
Double blind -all involved are blinded
Placebo
2
Treatment
Medicine |
Bepotastine besilate OD tablets administered to 35 subjects twice daily on the Japanese cedar pollen exposure day(30 minutes after the start of exposure and night).
The next day and the following day, also administered twice daily.
Placebo tablets administered to 35 subjects twice daily on the Japanese cedar pollen exposure day(30 minutes after the start of exposure and night).
The next day and the following day, also administered twice daily.
20 | years-old | <= |
65 | years-old | > |
Male and Female
1)CAP-RAST score against Japanese cedar pollen over class 2 within the last 3 years.
2)Have experience with cedar pollen exposure in the OHIO Chamber in the past, patients with nasal symptoms.
3)Patients who are considered eligible medical examination results investigator doctors.
4)Written informed consent is required.
1)Some patients with mucosal lesion of the nose and eyes.
2)Patients with severe perennial allergic rhinitis or requiring treatment.
3)Patients who received steroid injections within 6 months.
4)Patients with respiratory disease such as asthma.
5)Patients with past history of anaphylaxis.
6)Patients who have the hypersensitivity to study drug.
7)Pregnancy,breast-feeding woman,potential pregnancy,patients who wish to become pregnant during this study.
8)Patients who were judged to be unsuitable for patient enrollment by their doctor (Patients who have undergone nasal operation or patients who have receiving immunotherapy).
70
1st name | |
Middle name | |
Last name | Kimihiro Okubo |
Nippon Medical School
Department of Otorhinolaryngology and Head/neck Surgery
1-1-5 Sendagi,Bunkyo-ku,Tokyo 113-8603,Japan
1st name | |
Middle name | |
Last name | Satoko Shimizu |
Tokyo Reserch Center of Clinical Pharmacology co.,ltd.
Clinical Trial Operations Support Section,Customer Relations Dept.
s-shimizu@trcp.co.jp
Nippon Medical School
Japan Allergy Foundation
Non profit foundation
NO
医療法人社団 信濃会 左門町クリニック (東京都)
2012 | Year | 06 | Month | 26 | Day |
Unpublished
Completed
2012 | Year | 06 | Month | 06 | Day |
2012 | Year | 07 | Month | 01 | Day |
2012 | Year | 07 | Month | 29 | Day |
2012 | Year | 08 | Month | 31 | Day |
2012 | Year | 08 | Month | 31 | Day |
2012 | Year | 06 | Month | 25 | Day |
2013 | Year | 01 | Month | 16 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009718